DRUG DELIVERY TO A JOINT

• US 20110238016A1
• Filed: 06/08/2011
• Published: 09/29/2011
• Est. Priority Date: 01/13/2004
• Status: Abandoned Application

• Current Assignee: Hospital For Special Surgery (The NewYork-Presbyterian Healthcare System, Inc.)
• Original Assignee: Hospital For Special Surgery (The NewYork-Presbyterian Healthcare System, Inc.)
• Inventors: Koski, John A., HOTCHKISS, Robert N.
• Application Number:
  US13/156,079
• Publication Number:
  US 20110238016A1
• Time in Patent Office: Days
• US Class Current: 604/175
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/222 Steroids, e.g. corticosteroids
• CPC Class Codes: A61L 2300/402 Anaestetics, analgesics, e.g. lidocaine
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 37/0069 Devices for implanting pellets, e.g. markers or solid medicaments for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

A drug delivery device may include a base to be percutaneously affixable in an attachment zone of a synovial joint and a sustained-release drug carrier coupled to the base. The drug delivery device may also include an access device to provide access to the attachment zone. The attachment zone may comprise a non-articulating portion of a bone and/or cartilage with the synovial joint and the drug carrier may elute the drug into the synovial fluid sufficient to sustain a therapeutically effective concentration of the drug in the synovial fluid for at least 8 hours.

Claims

1. A sustained-release intra-articular drug delivery device, comprising:

a base, so sized and shaped as to be percutaneously affixable in an attachment zone of a synovial joint, the attachment zone comprising a non-articulating portion of bone and/or cartilage with the synovial joint; and

a sustained-release drug carrier coupled to the base, the carrier including a drug, the carrier so formed as to elute the drug into synovial fluid, upon implantation of the device in a joint, sufficient to sustain a therapeutically effective concentration of the drug in the synovial fluid for at least 8 hours.

2. The drug delivery device of claim 1, wherein the base comprises at least one barb.

3. The drug delivery device of claim 2, wherein the at least one barb is retractable.

4. The drug delivery device of claim 2, wherein the at least one barb is expandable.

5. The drug delivery device of claim 1, wherein the base has a variable diameter.

6. The drug delivery device of claim 5, wherein a first diameter is selected to facilitate insertion and a second diameter is selected to facilitate affixation.

7. The drug delivery device of claim 1, wherein the base is configured to be substantially flush with the bone surface after affixation.

8. The drug delivery device of claim 1, wherein the drug carrier is replaceable.

9. The drug delivery device of claim 1, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to an articulating surface within the synovial joint.

10. The drug delivery device of claim 9, wherein the band extends from about 0.5 millimeters to about 1 centimeter away from the articulating surface.

11. The drug delivery device of claim 1, wherein the synovial joint is a hip joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the hip.

12. The drug delivery device of claim 11, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of a femoral head, and an acetabulum.

13. The drug delivery device of claim 1, wherein the synovial joint is a knee joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the knee.

14. The drug delivery device of claim 13, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of a tibial plateau, a femoral condyle, a patellofemoral area, the medial rim of a femoral trochlea, the lateral rim of a femoral trochlea, and the periphery of an intercondylar notch.

15. The drug delivery device of claim 1, wherein the synovial joint is a shoulder joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the shoulder.

16. The drug delivery device of claim 15, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of the anatomical neck of a humerus, a glenoid cavity, and a glenoid neck.

17. The drug delivery device of claim 1, wherein the synovial joint is an arthroplastic joint comprising at least one prosthesis, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the joint.

18. The drug delivery device of claim 17, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to the at least one prosthesis.

19. A sustained-release intra-articular drug delivery device, comprising:

a base, so sized and shaped as to be percutaneously affixable in an attachment zone of a synovial joint, the attachment zone comprising a non-articulating portion of bone and/or cartilage with the synovial joint;

a sustained-release drug carrier coupled to the base, the carrier including a drug, the carrier so formed as to elute the drug into synovial fluid, upon implantation of the device in a joint, sufficient to sustain a therapeutically effective concentration of the drug in the synovial fluid for at least 8 hours; and

an access device, so sized and shaped as to provide access to the attachment zone.

20. The drug delivery device of claim 19, wherein the base comprises at least one barb.

21. The drug delivery device of claim 20, wherein the at least one barb is retractable.

22. The drug delivery device of claim 20, wherein the at least one barb is expandable.

23. The drug delivery device of claim 19, wherein the base has a variable diameter.

24. The drug delivery device of claim 23, wherein a first diameter is selected to facilitate insertion and a second diameter is selected to facilitate affixation.

25. The drug delivery device of claim 19, wherein the base is configured to be substantially flush with the bone surface after affixation.

26. The drug delivery device of claim 19, wherein the drug carrier is replaceable.

27. The drug delivery device of claim 19, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to an articulating surface within the synovial joint.

28. The drug delivery device of claim 27, wherein the band extends from about 0.5 millimeters to about 1 centimeter away from the articulating surface.

29. The drug delivery device of claim 19, wherein the synovial joint is a hip joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the hip.

30. The drug delivery device of claim 29, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of a femoral head, and an acetabulum.

31. The drug delivery device of claim 19, wherein the synovial joint is a knee joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the knee.

32. The drug delivery device of claim 31, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of a tibial plateau, a femoral condyle, a patellofemoral area, the medial rim of a femoral trochlea, the lateral rim of a femoral trochlea, and the periphery of an intercondylar notch.

33. The drug delivery device of claim 19, wherein the synovial joint is a shoulder joint, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the shoulder.

34. The drug delivery device of claim 33, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to at least one of the anatomical neck of a humerus, a glenoid cavity, and a glenoid neck.

35. The drug delivery device of claim 19, wherein the synovial joint is an arthroplastic joint comprising at least one prosthesis, and the attachment zone comprises a non-articulating portion of bone and/or cartilage within the joint.

36. The drug delivery device of claim 35, wherein the attachment zone comprises a band of bone and/or cartilage adjacent to the at least one prosthesis.